Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Pharm Res. 2015 May 6;32(10):3170–3187. doi: 10.1007/s11095-015-1695-1

Table 4.

Deposition fractions (as a percentage of aerosolized dose) based on CFD predictions compared with the in vivo data of Newman et al. (52) (in parentheses) for the Respimat SMI operated with a SD waveform and PIFR of 41.2 LPM.

Device NA (21.9)
MT 39.5 (37.1)
Central lung (trachea excluded) 9.1 (11.0)
Intermediate and peripheral lung 28.7 (28.2)
Trachea-B3 1.0
B4-B7 8.9
B8-B15 9.2
Alveolar 19.5